# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Sales Highlights (unaudited):Global• Q1 sales AUD$2.0 million up 34% on prior comparative period (pcp)Australia • Q1 sales AUD$...
US Tariffs: Immuron does not anticipate any material impact from the recently announced US tariffs on pharmaceutical productsTr...
Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to p...
GlobalAnnual sales AUD$7.3 million up 49% on prior yearJune 2025 Quarter AUD$2.0 million up 55% on prior yearAustralia Annual s...